MAP
AGIO icon

Moody Aldrich Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Moody Aldrich Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,938
Closed -$1.77M – 93
2018
Q3 		$1.77M Buy
22,938
+3,579
+18% +$288K 0.51% 81
2018
Q2 		$1.63M Buy
+19,359
New +$1.69M 0.58% 73

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Moody Aldrich Partners's AGIO Position: Q4 2018 in Review

Moody Aldrich Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2018, closing a stake of 22,938 shares — an estimated $1.77M sold.

Moody Aldrich Partners first reported a position in AGIO in Q2 2018 and held it in 2 quarters. The position peaked at $1.77M in Q3 2018. 196 funds tracked by Wall St. Rank hold AGIO as of Q4 2018.

  • Moody Aldrich Partners reported no remaining Agios Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Moody Aldrich Partners sold 22,938 Agios Pharmaceuticals shares in Q4 2018, an estimated $1.77M.
  • Moody Aldrich Partners first reported a position in Agios Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Moody Aldrich Partners's Agios Pharmaceuticals position peaked at $1.77M in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2018.

Based on Moody Aldrich Partners's 13F filing for Q4 2018, filed 12 Feb 2019.